Pancreatic cancer (PC) is a lethal tumour with a 5-year survival rate of 11 % [1]. Although most PCs are sporadic, about 10 % of patients with PC are encountered among subjects with a strong family history or carrying predisposing germline mutations, defining these patients as high-risk individuals (HRIs). The risk of developing PC in these subjects varies depending on the family history and/or the specific underlying genetic mutation, ranging from a relative risk of about 2.5 to 132-fold higher…